vs
Doximity, Inc.（DOCS）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
Doximity, Inc.的季度营收约是再鼎医药的1.5倍（$185.1M vs $127.1M），再鼎医药同比增速更快（17.1% vs 9.8%），过去两年Doximity, Inc.的营收复合增速更高（25.2% vs 20.8%）
Doximity Inc成立于2010年，是面向医疗专业人士的线上社交服务平台，为平台会员提供精选医疗资讯、远程医疗工具，以及病例协作相关功能，助力医疗从业者高效交流信息、开展诊疗相关工作。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
DOCS vs ZLAB — 直观对比
营收规模更大
DOCS
是对方的1.5倍
$127.1M
营收增速更快
ZLAB
高出7.4%
9.8%
两年增速更快
DOCS
近两年复合增速
20.8%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $185.1M | $127.1M |
| 净利润 | $61.6M | — |
| 毛利率 | 89.9% | 51.0% |
| 营业利润率 | 38.9% | -54.6% |
| 净利率 | 33.3% | — |
| 营收同比 | 9.8% | 17.1% |
| 净利润同比 | -18.1% | — |
| 每股收益（稀释后） | $0.31 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOCSZLAB
| Q4 25 | $185.1M | $127.1M | ||
| Q3 25 | $168.5M | $115.4M | ||
| Q2 25 | $145.9M | $109.1M | ||
| Q1 25 | $138.3M | $105.7M | ||
| Q4 24 | $168.6M | $108.5M | ||
| Q3 24 | $136.8M | $101.8M | ||
| Q2 24 | $126.7M | $100.1M | ||
| Q1 24 | $118.1M | $87.1M |
净利润DOCSZLAB
| Q4 25 | $61.6M | — | ||
| Q3 25 | $62.1M | $-36.0M | ||
| Q2 25 | $53.3M | $-40.7M | ||
| Q1 25 | $62.5M | $-48.4M | ||
| Q4 24 | $75.2M | — | ||
| Q3 24 | $44.2M | $-41.7M | ||
| Q2 24 | $41.4M | $-80.3M | ||
| Q1 24 | $40.6M | $-53.5M |
毛利率DOCSZLAB
| Q4 25 | 89.9% | 51.0% | ||
| Q3 25 | 90.3% | 59.5% | ||
| Q2 25 | 89.2% | 60.6% | ||
| Q1 25 | 89.5% | 63.6% | ||
| Q4 24 | 91.6% | 61.5% | ||
| Q3 24 | 90.0% | 64.1% | ||
| Q2 24 | 89.3% | 64.9% | ||
| Q1 24 | 89.4% | 61.4% |
营业利润率DOCSZLAB
| Q4 25 | 38.9% | -54.6% | ||
| Q3 25 | 37.8% | -42.3% | ||
| Q2 25 | 37.4% | -50.3% | ||
| Q1 25 | 35.2% | -53.3% | ||
| Q4 24 | 47.4% | -62.6% | ||
| Q3 24 | 38.8% | -66.6% | ||
| Q2 24 | 36.4% | -76.0% | ||
| Q1 24 | 35.5% | -80.7% |
净利率DOCSZLAB
| Q4 25 | 33.3% | — | ||
| Q3 25 | 36.8% | -31.2% | ||
| Q2 25 | 36.5% | -37.3% | ||
| Q1 25 | 45.2% | -45.8% | ||
| Q4 24 | 44.6% | — | ||
| Q3 24 | 32.3% | -40.9% | ||
| Q2 24 | 32.7% | -80.2% | ||
| Q1 24 | 34.4% | -61.4% |
每股收益（稀释后）DOCSZLAB
| Q4 25 | $0.31 | $-0.05 | ||
| Q3 25 | $0.31 | $-0.03 | ||
| Q2 25 | $0.27 | $-0.04 | ||
| Q1 25 | $0.31 | $-0.04 | ||
| Q4 24 | $0.37 | $-0.09 | ||
| Q3 24 | $0.22 | $-0.04 | ||
| Q2 24 | $0.21 | $-0.08 | ||
| Q1 24 | $0.20 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $64.8M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $979.3M | $715.5M |
| 总资产 | $1.2B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DOCSZLAB
| Q4 25 | $64.8M | $689.6M | ||
| Q3 25 | $169.2M | $717.2M | ||
| Q2 25 | $137.3M | $732.2M | ||
| Q1 25 | $209.6M | $757.3M | ||
| Q4 24 | $165.3M | $779.7M | ||
| Q3 24 | $184.2M | $616.1M | ||
| Q2 24 | $111.4M | $630.0M | ||
| Q1 24 | $96.8M | $650.8M |
股东权益DOCSZLAB
| Q4 25 | $979.3M | $715.5M | ||
| Q3 25 | $1.1B | $759.9M | ||
| Q2 25 | $1.0B | $791.7M | ||
| Q1 25 | $1.1B | $810.8M | ||
| Q4 24 | $1.0B | $840.9M | ||
| Q3 24 | $961.2M | $667.7M | ||
| Q2 24 | $913.6M | $704.2M | ||
| Q1 24 | $901.4M | $762.2M |
总资产DOCSZLAB
| Q4 25 | $1.2B | $1.2B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.2B | $1.2B | ||
| Q1 25 | $1.3B | $1.2B | ||
| Q4 24 | $1.2B | $1.2B | ||
| Q3 24 | $1.1B | $985.3M | ||
| Q2 24 | $1.1B | $987.4M | ||
| Q1 24 | $1.1B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.9M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | 0.99× | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流DOCSZLAB
| Q4 25 | $60.9M | $-26.0M | ||
| Q3 25 | $93.9M | $-32.0M | ||
| Q2 25 | $62.1M | $-31.0M | ||
| Q1 25 | $98.5M | $-61.7M | ||
| Q4 24 | $65.2M | $-55.8M | ||
| Q3 24 | $68.3M | $-26.8M | ||
| Q2 24 | $41.2M | $-42.2M | ||
| Q1 24 | $63.9M | $-90.1M |
自由现金流DOCSZLAB
| Q4 25 | — | $-26.7M | ||
| Q3 25 | — | $-35.0M | ||
| Q2 25 | — | $-33.9M | ||
| Q1 25 | — | $-63.2M | ||
| Q4 24 | — | $-58.4M | ||
| Q3 24 | — | $-28.2M | ||
| Q2 24 | — | $-42.9M | ||
| Q1 24 | — | $-91.1M |
自由现金流率DOCSZLAB
| Q4 25 | — | -21.0% | ||
| Q3 25 | — | -30.4% | ||
| Q2 25 | — | -31.1% | ||
| Q1 25 | — | -59.9% | ||
| Q4 24 | — | -53.8% | ||
| Q3 24 | — | -27.7% | ||
| Q2 24 | — | -42.9% | ||
| Q1 24 | — | -104.5% |
资本支出强度DOCSZLAB
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | 0.0% | 1.5% | ||
| Q4 24 | 0.0% | 2.4% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | 0.0% | 0.7% | ||
| Q1 24 | 0.0% | 1.1% |
现金转化率DOCSZLAB
| Q4 25 | 0.99× | — | ||
| Q3 25 | 1.51× | — | ||
| Q2 25 | 1.16× | — | ||
| Q1 25 | 1.58× | — | ||
| Q4 24 | 0.87× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 1.00× | — | ||
| Q1 24 | 1.57× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOCS
| Subscription | $175.4M | 95% |
| Service Other | $9.7M | 5% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
